{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:02:08Z","timestamp":1776258128052,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.hfc.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T07:37:19Z","timestamp":1654069039000},"page":"489-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical Practice Guidelines in Cardio-Oncology"],"prefix":"10.1016","volume":"18","author":[{"given":"Darryl P.","family":"Leong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hfc.2022.02.002_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.hfc.2022.02.002_bib2","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.002_bib3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.002_bib4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.hfc.2022.02.002_bib5","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","author":"Herrmann","year":"2021","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.hfc.2022.02.002_bib6","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.hfc.2022.02.002_bib7","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.hfc.2022.02.002_bib8","article-title":"Left ventricular diastolic function following anthracycline-based chemotherapy in patients with breast cancer without previous cardiac disease: a meta-analysis","volume":"10","author":"Mincu","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.hfc.2022.02.002_bib9","doi-asserted-by":"crossref","DOI":"10.1007\/s10554-021-02470-2","article-title":"Right ventricular function during trastuzumab therapy for breast cancer","author":"Mazzutti","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.002_bib10","doi-asserted-by":"crossref","first-page":"17132","DOI":"10.1038\/s41598-021-96630-y","article-title":"Cardiac magnetic resonance assessment of right ventricular remodeling after anthracycline therapy","volume":"11","author":"de Souza","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.hfc.2022.02.002_bib11","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","article-title":"Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis","volume":"3","author":"Alhussein","year":"2021","journal-title":"CJC Open"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.002_bib12","first-page":"544.e1","article-title":"Reversible cabozantinib-induced cardiomyopathy","volume":"35","author":"Alhussein","year":"2019","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.002_bib13","first-page":"36","article-title":"Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia","volume":"7","author":"Kim","year":"2021","journal-title":"Cardiooncology"},{"issue":"22","key":"10.1016\/j.hfc.2022.02.002_bib14","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.hfc.2022.02.002_bib15","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.002_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2022.02.002_bib17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/heartjnl-2019-316297","article-title":"Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity","volume":"106","author":"Lambert","year":"2020","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.002_bib18","first-page":"e012459","article-title":"Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 years of follow-up. circulation cardiovascular imaging","volume":"14","author":"Giusca","year":"2021"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.002_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaccao.2021.04.011","article-title":"Cardiac magnetic resonance in cardio-oncology: advantages, importance of expediency, and considerations to navigate pre-authorization","volume":"3","author":"O'Quinn","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"22","key":"10.1016\/j.hfc.2022.02.002_bib20","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.002_bib21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2022.02.002_bib24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.002_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.002_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaccao.2019.10.001","article-title":"Effect of eplerenone on diastolic function in women receiving anthracycline-based chemotherapy for breast cancer","volume":"1","author":"Davis","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.002_bib27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s11154-021-09675-9","article-title":"Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment: a review","volume":"22","author":"Lau","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"14","key":"10.1016\/j.hfc.2022.02.002_bib28","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4 Pt 1","key":"10.1016\/j.hfc.2022.02.002_bib29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0002-8703(83)90080-7","article-title":"Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance","volume":"106","author":"Choi","year":"1983","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.002_bib30","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0002-9343(87)90212-9","article-title":"Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography","volume":"82","author":"Schwartz","year":"1987","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.002_bib31","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hfc.2022.02.002_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.002_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"A\u00a0phase I trial evaluating the safety of continuing trastuzumab despite mild cardiotoxicity","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncology"},{"issue":"23","key":"10.1016\/j.hfc.2022.02.002_bib34","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Randomized controlled trial","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2022.02.002_bib35","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","author":"Halliday","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.002_bib36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hfc.2022.02.002_bib37","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.002_bib38","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.002_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.002_bib40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.002_bib41","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/cncr.21662","article-title":"Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial","volume":"106","author":"Rifkin","year":"2006","journal-title":"Cancer"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713622000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713622000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:42:17Z","timestamp":1761554537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713622000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1551713622000034"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2022.02.002","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Practice Guidelines in Cardio-Oncology","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}